Background: From August to September 2022, Urumqi, the capital of the Xinjiang Uygur Autonomous Region in China, faced its largest COVID-19 outbreak caused by the emergence of the SARS-CoV-2 Omicron BA.5.2 variants. Although the superspreading of COVID-19 played an important role in triggering large-scale outbreaks, little was known about the superspreading potential and heterogeneity in the transmission of Omicron BA.5 variants.

Methods: In this retrospective observational, contact tracing study, we identified 1139 laboratory-confirmed COVID-19 cases of Omicron BA.5.2 variants, and 51 323 test-negative close contacts in Urumqi from 7 August to 7 September 2022. By using detailed contact tracing information and exposure history of linked case-contact pairs, we described stratification in contact and heterogeneity in transmission across different demographic strata, vaccine statuses, and contact settings. We adopted beta-binomial models to characterise the secondary attack rate (SAR) distribution among close contacts and modelled COVID-19 transmission as a branching process with heterogeneity in transmission governed by negative binomial models.

Results: After the city lockdown, the mean case cluster size decreased from 2.0 (before lockdown) to 1.6, with decreased proportions of contacts in workplace and community settings compared with household settings. We estimated that 14% of the most infectious index cases generated 80% transmission, whereas transmission in the community setting presented the highest heterogeneity, with 5% index cases seeding 80% transmission. Compared with zero, one, and two doses of inactivated vaccine (Sinopharm), index cases with three doses of vaccine had a lower risk of generating secondary cases in terms of the reproduction number. Contacts of female cases, cases with ages 0-17 years, and household settings had relatively higher SAR.

Conclusions: In the context of intensive control measures, active case detection, and relatively high vaccine coverage, but with an infection-naive population, our findings suggested high heterogeneity in the contact and transmission risks of Omicron BA.5 variants across different demographic strata, vaccine statuses, and contact settings. Given the rapid evolution of SARS-CoV-2, investigating the distribution of transmission not only helped promote public awareness and preparedness among high-risk groups, but also highlighted the importance of continuously monitoring the transmission characteristics of genetic variants of SARS-CoV-2.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193892PMC
http://dx.doi.org/10.7189/jogh.13.06018DOI Listing

Publication Analysis

Top Keywords

omicron ba5
12
heterogeneity transmission
12
transmission
11
sars-cov-2 omicron
8
ba5 variants
8
august september
8
september 2022
8
omicron ba52
8
ba52 variants
8
contact tracing
8

Similar Publications

Article Synopsis
  • - SARS-CoV-2 is still a major cause of death in North America, and this study examines how methotrexate and tumor necrosis factor inhibitors (TNFi) affect vaccine responses in patients with immune-mediated inflammatory diseases (IMID).
  • - Researchers collected and analyzed serum samples from 479 adults with conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) across Canada to evaluate neutralization responses to COVID-19 vaccination.
  • - The results indicated that both methotrexate and TNFi independently reduced the ability to neutralize the virus, underscoring the need for careful vaccination strategies as COVID-19 remains widespread.
View Article and Find Full Text PDF

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia.

BMC Infect Dis

August 2024

Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, No.1 Jalan Setia Murni U13/52, Seksyen U13, Shah Alam, Selangor, 40170, Malaysia.

Background: The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood. The purpose of this study was to assess how nirmatrelvir/ritonavir treatment affected both PCC and health-related quality of life.

Methods: This retrospective cohort study enrolled 2,524 adults aged 18 years and older who were eligible for nirmatrelvir/ritonavir between July 14 to November 14, 2022.

View Article and Find Full Text PDF
Article Synopsis
  • Although the Omicron variant of SARS-CoV-2 has many mutations, the backbone of its spike protein remains largely the same, providing a stable target for vaccine design.
  • Researchers created several subunit vaccines using this stable backbone along with various receptor-binding domains from different SARS-CoV-2 variants to test their immune response capabilities.
  • The S-6P-Delta-RBD vaccine showed strong effectiveness, generating broad neutralizing antibodies and offering complete protection against severe outcomes from Delta and Omicron infections in mice, indicating its potential as a universal COVID-19 vaccine.
View Article and Find Full Text PDF

Background: Information on Paxlovid™ effectiveness must be monitored and updated in real world scenarios. Our research question was what is the effectiveness of Paxlovid™ in adult patients with COVID-19? Therefore, we investigated the effectiveness of Paxlovid™ on reducing the incidence of pneumonia, hospitalization, and mortality in a cohort of COVID-19 positive adult patients from northeast Mexico.

Methods: A retrospective cohort study of COVID-19 positive adult patients from Nuevo Leon, Mexico from December 2020 to May 2023 (after Omicron BA-5 circulation) was performed.

View Article and Find Full Text PDF

The emergence of the variant of concern Omicron (B.1.1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!